Perfusio-Based Nucleic Acid Pharmaceutical Delivery, Shorter Development Timelines, and Commercialization
First written in FY2025. 8 of 12 entries say "Advanced", first in 2026-05-11. Latest entry: 2026-10-13.
No other company in this theme has enough history to compare yet.
- FY2026-H1AdvancedAnnual report
「Regarding Perfusio, the drug delivery system devised by the company and patented in December 2025, we selected potential partners and held in-person consultations with the PMDA (Pharmaceuticals and Medical Devices Agency, an independent administrative agency that ensures the efficacy, safety and quality of pharmaceuticals and medical devices) as part of preparations to begin sales during fiscal 2027.」
Preparations for commercialization of Perfusio became more concrete, including selecting partner companies and holding face-to-face consultations with PMDA toward obtaining marketing authorization to begin sales within FY2027. - FY2025First statedAnnual report
「The goal is to commercialize and begin sales of this DDS during the period covered by the medium-term management plan through FY2027. If progress is most favorable, we aim to use this DDS to reduce the clinical trial period and costs for our pipelines to approximately one-fifth.」
The company named its proprietary DDS, which delivers and collects drugs in target organs using a catheter, Perfusio, and disclosed for the first time its targets of practical implementation and commencement of sales by FY2027 and reducing clinical trial periods and costs to approximately one-fifth. - 2026-03-02First statedGeneral Meetings of Shareholders
「We will make effective use of this method and work to shorten clinical trial periods and reduce costs for our in-house pipeline in order to enhance our future value.」
The company named its catheter-based drug delivery system Perfusio and recorded for the first time its policy of using it to shorten clinical trial periods and reduce costs for its in-house pipeline.